Connect Biopharma Ownership
| CNTB Stock | USD 0.81 0.01 1.26% |
Connect |
Connect Stock Ownership Analysis
About 41.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.4. Some equities with similar Price to Book (P/B) outperform the market in the long run. Connect Biopharma recorded a loss per share of 0.39. The entity had not issued any dividends in recent years. Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company was founded in 2012 and is headquartered in Taicang, China. Connect Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 108 people. For more info on Connect Biopharma Holdings please contact Barry PharmD at 858 727 1040 or go to https://www.connectbiopharm.com.Besides selling stocks to institutional investors, Connect Biopharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Connect Biopharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Connect Biopharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Connect Biopharma Quarterly Liabilities And Stockholders Equity |
|
About 41.0% of Connect Biopharma Holdings are currently held by insiders. Unlike Connect Biopharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Connect Biopharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Connect Biopharma's insider trades
Connect Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Connect Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Connect Biopharma Holdings backward and forwards among themselves. Connect Biopharma's institutional investor refers to the entity that pools money to purchase Connect Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-12-31 | 121 | Sbi Securities Co Ltd | 2024-12-31 | 6.0 | Blackrock Inc | 2024-12-31 | 0.0 | Keudell/morrison Wealth Management | 2024-12-31 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 0.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Bml Capital Management Llc | 2024-12-31 | 2.1 M | Ubs O'connor Llc | 2024-12-31 | 510.7 K | Rsm Us Wealth Management Llc | 2024-12-31 | 160.9 K | Renaissance Technologies Corp | 2024-12-31 | 134.7 K | Royal Bank Of Canada | 2024-12-31 | 80.4 K |
Connect Biopharma Outstanding Bonds
Connect Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Connect Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Connect bonds can be classified according to their maturity, which is the date when Connect Biopharma Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| CONNECTICUT LT PWR Corp BondUS207597DV42 | View | |
| CONNECTICUT LT PWR Corp BondUS207597EG65 | View | |
| CONNECTICUT LT PWR Corp BondUS207597EH49 | View | |
| CONNECTICUT LT PWR Corp BondUS207597EJ05 | View | |
| CONNECTICUT LT PWR Corp BondUS207597EL50 | View | |
| US207597EM34 Corp BondUS207597EM34 | View | |
| ES 205 01 JUL 31 Corp BondUS207597EN17 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.